Berberine and berberine nanoformulations in cancer therapy: Focusing on lung cancer

Fuente: Wiley Open Access
Guardado en:
Detalles Bibliográficos
Autores principales: Chou‐Yi Hsu, Harikumar Pallathadka, Jitendra Gupta, Haowei Ma, Hamzah H. K. Al‐Shukri, A. K. Kareem, Ahmed Hussein Zwamel, Yasser Fakri Mustafa
Formato: Artículo Open Access
Publicado: Wiley 2024
Materias:
Acceso en línea:
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
_version_ 1867010390523641856
author Chou‐Yi Hsu
Harikumar Pallathadka
Jitendra Gupta
Haowei Ma
Hamzah H. K. Al‐Shukri
A. K. Kareem
Ahmed Hussein Zwamel
Yasser Fakri Mustafa
author_facet Chou‐Yi Hsu
Harikumar Pallathadka
Jitendra Gupta
Haowei Ma
Hamzah H. K. Al‐Shukri
A. K. Kareem
Ahmed Hussein Zwamel
Yasser Fakri Mustafa
Chou‐Yi Hsu
Harikumar Pallathadka
Jitendra Gupta
Haowei Ma
Hamzah H. K. Al‐Shukri
A. K. Kareem
Ahmed Hussein Zwamel
Yasser Fakri Mustafa
collection Wiley Open Access
contents Berberine and berberine nanoformulations in cancer therapy: Focusing on lung cancer Chou‐Yi Hsu Harikumar Pallathadka Jitendra Gupta Haowei Ma Hamzah H. K. Al‐Shukri A. K. Kareem Ahmed Hussein Zwamel Yasser Fakri Mustafa Phytotherapy Research AbstractLung cancer is the second most prevalent cancer and ranks first in cancer‐related death worldwide. Due to the resistance development to conventional cancer therapy strategies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, various natural products and their extracts have been revealed as alternatives. Berberine (BBR), which is present in the stem, root, and bark of various trees, could exert anticancer activities by regulating tumor cell proliferation, apoptosis, autophagy, metastasis, angiogenesis, and immune responses via modulating several signaling pathways within the tumor microenvironment. Due to its poor water solubility, poor pharmacokinetics/bioavailability profile, and extensive p‐glycoprotein‐dependent efflux, BBR application in (pre) clinical studies is restricted. To overcome these limitations, BBR can be encapsulated in nanoparticle (NP)‐based drug delivery systems, as monotherapy or combinational therapy, and improve BBR therapeutic efficacy. Nanoformulations also facilitate the selective delivery of BBR into lung cancer cells. In addition to the anticancer activities of BBR, especially in lung cancer, here we reviewed the BBR nanoformulations, including polymeric NPs, metal‐based NPs, carbon nanostructures, and others, in the treatment of lung cancer. 10.1002/ptr.8255 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1002/ptr.8255
format Artículo Open Access
id wiley_oa_10_1002_ptr_8255
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2024
publisher Wiley
record_format wiley_oa
spellingShingle Berberine and berberine nanoformulations in cancer therapy: Focusing on lung cancer
Chou‐Yi Hsu
Harikumar Pallathadka
Jitendra Gupta
Haowei Ma
Hamzah H. K. Al‐Shukri
A. K. Kareem
Ahmed Hussein Zwamel
Yasser Fakri Mustafa
Phytotherapy Research
Berberine and berberine nanoformulations in cancer therapy: Focusing on lung cancer Chou‐Yi Hsu Harikumar Pallathadka Jitendra Gupta Haowei Ma Hamzah H. K. Al‐Shukri A. K. Kareem Ahmed Hussein Zwamel Yasser Fakri Mustafa Phytotherapy Research AbstractLung cancer is the second most prevalent cancer and ranks first in cancer‐related death worldwide. Due to the resistance development to conventional cancer therapy strategies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, various natural products and their extracts have been revealed as alternatives. Berberine (BBR), which is present in the stem, root, and bark of various trees, could exert anticancer activities by regulating tumor cell proliferation, apoptosis, autophagy, metastasis, angiogenesis, and immune responses via modulating several signaling pathways within the tumor microenvironment. Due to its poor water solubility, poor pharmacokinetics/bioavailability profile, and extensive p‐glycoprotein‐dependent efflux, BBR application in (pre) clinical studies is restricted. To overcome these limitations, BBR can be encapsulated in nanoparticle (NP)‐based drug delivery systems, as monotherapy or combinational therapy, and improve BBR therapeutic efficacy. Nanoformulations also facilitate the selective delivery of BBR into lung cancer cells. In addition to the anticancer activities of BBR, especially in lung cancer, here we reviewed the BBR nanoformulations, including polymeric NPs, metal‐based NPs, carbon nanostructures, and others, in the treatment of lung cancer. 10.1002/ptr.8255 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Berberine and berberine nanoformulations in cancer therapy: Focusing on lung cancer
topic Phytotherapy Research
url https://onlinelibrary.wiley.com/doi/10.1002/ptr.8255